65,437 trials
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Progression-free Survival — 1.8; 3.7 months
Schizophrenia · Schizoaffective Disorder
Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken
Pulmonary Tuberculosis
Primary: Number of Participants Suffering From Treatment Failure/ Relapse (Unfavourable Outcome) Among Rifampicin Resistant Group. — 12; 8; 67; 73 participants
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Spinal Cord Injury
Primary: Pressure Ulcer Geometry — 3.5; 4.9; 2.9; 3.0 cm
Breast Cancer
Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months
Cystic Fibrosis
Primary: Cohort 1: Safety and Tolerability Based on Adverse Events (AEs) — 12; 29; 15; 14 participants
Pancreatic Pseudocyst(s)
Primary: Safety/Adverse Event Outcome Measure 1 — 100 percentage of patients
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events — 6; 0; 1; 1 participants
Homozygous Familial Hypercholesterolemia
Primary: Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -16.5 percent change
Rheumatoid Arthritis
Primary: Percentage (%) of Participants Receiving Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in Monotherapy as Current Treatment for RA According to National…
Solid Tumours
Primary: Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) — 6; 1 Participants
Hypersensitivity · Anaphylaxis
Primary: Percentage of Participants With Adjudicated Symptoms of Hypersensitivity — 1.3; 6.6; 9.5 percentage of participants
Nosocomial Infections
Primary: Bacteremia — 3.52; 4.93 events per 1000 at-risk days
Hypogonadism
Primary: Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12 — 43; 217 participants — p=<0.001